Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With Schizophrenia

Brexpiprazole is currently approved in the United States for the treatment of schizophrenia and as adjunctive treatment of major depressive disorder. In Canada, it is approved for the treatment of schizophrenia. This study evaluated the pharmacokinetics (PK) and safety of brexpiprazole in Japanese p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Pharmacol
Main Authors: Ishigooka, Jun, Iwashita, Shuichi, Higashi, Koushi, Liew, Ei Leen, Tadori, Yoshihiro
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Pharmacokinetics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5763318/
https://ncbi.nlm.nih.gov/pubmed/28750151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.979
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados